Pharming Group NV (PHAR) News
Filter PHAR News Items
PHAR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PHAR News Highlights
- For PHAR, its 30 day story count is now at 4.
- Over the past 21 days, the trend for PHAR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PHAR are AGM, PRE and RARE.
Latest PHAR News From Around the Web
Below are the latest news stories about PHARMING GROUP NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.
Pharming announces sale of priority review voucherPharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. ("Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing. |
Pharming Group to attend the following Investor Conferences in JunePharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor conferences in the month of June: |
Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersPharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved. |
Pharming Group reports financial results for the first quarter of 2023Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023. |
Pharming Group's (AMS:PHARM) investors will be pleased with their decent 51% return over the last yearIt hasn't been the best quarter for Pharming Group N.V. ( AMS:PHARM ) shareholders, since the share price has fallen... |
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST. |
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands. |
Notice of First Quarter 2023 ResultsPharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023. |
Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023. |